Evoke Pharma (EVOK) Tops Q3 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to Evoke Pharma (EVOK) Tops Q3 EPS by 12c
November 12, 2015 4:06 PM EST
SOLANA BEACH, Calif., Nov. 12, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced its financial results for the third quarter ended September 30, 2015.
Dave Gonyer, R.Ph., President and CEO, stated, "This was an exciting quarter for Evoke, as we made further progress on our Phase 3 clinical trial and continued to approach pivotal data for EVK-001 while enhancing our financial position. As announced in late September, we have enrolled 75% of our trial in women with diabetic gastroparesis, which keeps us on... More
November 10, 2015 8:31 AM EST
SOLANA BEACH, Calif., Nov. 10, 2015 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that Dave Gonyer, R.Ph., President and CEO will be participating in the Brean Capital 2015 Life Sciences Summit on Monday, November 16, 2015 at the Millennium Broadway Hotel in New York City.
A copy of the corporate presentation will be posted to the company's website prior to the conference.
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development... More
